Rewriting Life

Copycat Cures

Biotech: Protein power, without the problems.

Proteins are key players in the biological processes that determine whether a person is sick or well. So not surprisingly, they form the basis for some of today’s most important and effective drugs. But in some ways, these large, complex biomolecules are far from being the perfect drugs: they’re chewed up in the stomach if taken by mouth, and many of them break down even when injected-severely limiting which proteins can be used. Now a number of biotech companies are reporting progress in designing smaller, more stable molecules that mimic the therapeutic action of proteins, opening the door to completely new drugs, and to the possibility of replacing some painful injections with equally effective pills.

In July, MetaPhore Pharmaceuticals of St. Louis announced the successful safety testing in humans of a “mimetic”-a drug that mimics the action of a human protein. The new drug is a copycat of a natural enzyme that disarms toxic free radicals, and it could eventually be used to treat cancer, arthritis, pain and even the aging process. But beyond all that, the drug demonstrates that a small engineered molecule can, in fact, take the place of a pharmaceutical protein.

Mimicking a protein was an accomplishment considered impossible just a decade ago, says Adrian Whitty, a senior scientist at Cambridge, MA, biotech giant Biogen. Only proteins, he explains, were thought capable of carrying out complex functions like, for example, triggering a chain of events inside a cell by binding to certain receptors on its surface. But in the mid-1990s, several groups showed that smaller molecules, initially found by random screening, could actually do the same job by binding to “hot spots” on those receptors. Since then, researchers have used either screening or computers to find or design more such targeted molecules, giving birth to mimetics.

This story is part of our December 2001 Issue
See the rest of the issue
Subscribe

A handful of companies have formed to tap mimetics’ potential. Locus Discovery, a Philadelphia-area startup, and Palo Alto, CA’s Affymax each say they have developed mimetics of erythropoietin, biotech’s best-selling protein-based drug, which helps reverse anemia caused by chemotherapy and kidney dialysis. Since erythropoietin must now be injected, a mimetic-based pill would be poised to capture its $6 billion market. If such pills can prove themselves in clinical trials, it could mark the end of painful injections for many patients.

Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.
Subscribe today

Uh oh–you've read all five of your free articles for this month.

Insider Premium

$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Premium.

  • Insider Premium {! insider.prices.premium !}*

    {! insider.display.menuOptionsLabel !}

    Our award winning magazine, unlimited access to our story archive, special discounts to MIT Technology Review Events, and exclusive content.

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

    Access to the Magazine archive. Over 24,000 articles going back to 1899 at your fingertips.

    Special Discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

    First Look. Exclusive early access to stories.

    Insider Conversations. Join in and ask questions as our editors talk to innovators from around the world.

You've read of free articles this month.